Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Peyre

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 12, 2018
Treatment of grade II-III intracranial meningioma with helical tomotherapyGeoffroy Boulle, Stefano Bracci, Kathryn Hitchcock, et al.
Blood Cells, Molecules & Diseases|December 4, 2018
Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the diseaseFrédéric Pouzoulet, Agusti Alentorn, Louis Royer-Perron, et al.
The Journal of Pathology|May 12, 2017
Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxiaGuillaume Gauchotte, Sébastien Hergalant, Charlène Vigouroux, et al.
European Journal of Internal Medicine|July 14, 2020
Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safetyBertrand Mathon, Alexandre Le Joncour, Franck Bielle, et al.
Clinical Neurology and Neurosurgery|June 20, 2020
Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastomaAntoine Seyve, Fernando Lozano-Sanchez, Alice Thomas, et al.
European Journal of Human Genetics : EJHG|April 1, 2022
ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosisD Gareth Evans, Stefania Mostaccioli, David Pang, et al.
Cancer Discovery|November 29, 2022
LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXLAram Ko, Mohammad Hasanain, Young Taek Oh, et al.
The New England Journal of Medicine|September 8, 2021
Somatic <i>PIK3CA</i> Mutations in Sporadic Cerebral Cavernous MalformationsMatthieu Peyre, Danielle Miyagishima, Franck Bielle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM TrialThomas Graillon, Marc Sanson, Chantal Campello, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 12, 2020
Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysisChristian Mirian, Anne Katrine Duun-Henriksen, Tareq Juratli, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 12, 2018
Treatment of grade II-III intracranial meningioma with helical tomotherapyGeoffroy Boulle, Stefano Bracci, Kathryn Hitchcock, et al.
Blood Cells, Molecules & Diseases|December 4, 2018
Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the diseaseFrédéric Pouzoulet, Agusti Alentorn, Louis Royer-Perron, et al.
The Journal of Pathology|May 12, 2017
Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxiaGuillaume Gauchotte, Sébastien Hergalant, Charlène Vigouroux, et al.
European Journal of Internal Medicine|July 14, 2020
Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safetyBertrand Mathon, Alexandre Le Joncour, Franck Bielle, et al.
Clinical Neurology and Neurosurgery|June 20, 2020
Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastomaAntoine Seyve, Fernando Lozano-Sanchez, Alice Thomas, et al.
European Journal of Human Genetics : EJHG|April 1, 2022
ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosisD Gareth Evans, Stefania Mostaccioli, David Pang, et al.
Cancer Discovery|November 29, 2022
LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXLAram Ko, Mohammad Hasanain, Young Taek Oh, et al.
The New England Journal of Medicine|September 8, 2021
Somatic <i>PIK3CA</i> Mutations in Sporadic Cerebral Cavernous MalformationsMatthieu Peyre, Danielle Miyagishima, Franck Bielle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM TrialThomas Graillon, Marc Sanson, Chantal Campello, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 12, 2020
Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysisChristian Mirian, Anne Katrine Duun-Henriksen, Tareq Juratli, et al.
Pageof 11